Last reviewed · How we verify
SYS6055
At a glance
| Generic name | SYS6055 |
|---|---|
| Sponsor | Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignancies (PHASE1)
- Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory Aggressive B-Cell Lymphoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SYS6055 CI brief — competitive landscape report
- SYS6055 updates RSS · CI watch RSS
- Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd portfolio CI